Connor, Clark & Lunn Investment Management Ltd. Dyne Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 41,157 shares of DYN stock, worth $608,712. This represents 0.01% of its overall portfolio holdings.
Number of Shares
41,157Holding current value
$608,712% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding DYN
# of Institutions
208Shares Held
102MCall Options Held
234KPut Options Held
238K-
Atlas Venture Life Science Advisors, LLC8.02MShares$119 Million35.54% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$109 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$102 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$101 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$101 Million0.13% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $766M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...